Yahoo Finance

Natera to Present New Renasight Data at ASN Kidney Week 2024

AUSTIN, Texas, October 22, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on ...
Nasdaq

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of ...
Business Wire

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that the Journal of the American Society of Nephrology recently published initial ...
Stockhouse

New Paper Highlights Clinical Utility of Natera's Renasight(TM) Test in the Management of Kidney Disease

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight™ in ...
FOX8 Cleveland

Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease

AUSTIN, Texas, April 19, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the results of a large, real-world study 1 demonstrating a high yield ...